Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People wit...( Study Shows Statin and Antioxidant T...)

Study Shows Statin and Antioxidant Therapy to be Superior to Statins Alone in Decreasing Cardiovascular Events in Diabetics with Haptoglobin 2-2

Genotype

MONTVALE, N.J., March 5 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announces the publication of a pre-planned sub-analysis from the ICARE study demonstrating that the addition of vitamin E to statin therapy prevented more cardiovascular events (heart attack, stroke and cardiovascular death) than statin therapy alone in patients with Diabetes Mellitus (DM) who tested positive for a genetic marker called Haptoglobin 2-2 (Hp2-2). This sub-analysis was published in the March issue of Arteriosclerosis, Thrombosis and Vascular Biology, a journal of the American Heart Association.

"These data are significant because they demonstrate that Haptoglobin testing may help physicians tailor optimal therapy for patients with diabetes who may be at risk for cardiovascular events. Physicians can better describe to their patients whether they are at high risk for a heart attack and whether they may anticipate a lower risk for heart attack if they take vitamin E. The knowledge of who would benefit from this nutriceutical is valuable for patients and physicians and may be cost saving for payers," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, Inc., which is developing a diagnostic product to identify Haptoglobin types. "This study demonstrates that positive clinical outcomes may be achieved with the application of patient selection. Thus, the 6,000,000 patients in the United States with diabetes and Hp2-2, who are at elevated risk for heart attack, could see that risk reduced by adding
'/>"/>